Compounds > adenosine monophosphate
Page last updated: 2024-08-17

adenosine monophosphate and Heart Defects, Congenital

adenosine monophosphate has been researched along with Heart Defects, Congenital in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Hanseus, K; Heying, R; Michel-Behnke, I; Milanesi, O; Sendzikaite, S1
Campbell, K; Gist, KM; Karimpour-Fard, A; Korst, A; Miyamoto, SD; Nakano, SJ; Stauffer, BL; Sucharov, CC; Wempe, MF; Zhou, W1

Other Studies

2 other study(ies) available for adenosine monophosphate and Heart Defects, Congenital

ArticleYear
COVID-19 FAQs in paediatric and congenital cardiology: AEPC position paper.
    Cardiology in the young, 2021, Volume: 31, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Anti-Arrhythmia Agents; Anticoagulants; Antiviral Agents; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Surgical Procedures; Cardiology; COVID-19; COVID-19 Drug Treatment; Heart Defects, Congenital; Heart Transplantation; Humans; Immunologic Factors; Infectious Disease Transmission, Vertical; Long QT Syndrome; Myocarditis; Myocardium; Pediatrics; Risk Assessment; SARS-CoV-2; Societies, Medical; Systemic Inflammatory Response Syndrome; Tachycardia, Ventricular

2021
Circulating cyclic adenosine monophosphate concentrations in milrinone treated paediatric patients after congenital heart surgery.
    Cardiology in the young, 2021, Volume: 31, Issue:9

    Topics: Adenosine Monophosphate; Cardiac Output, Low; Cardiotonic Agents; Child; Heart Defects, Congenital; Humans; Milrinone; Prospective Studies

2021